Article History
Received: 2 January 2022
Accepted: 12 October 2022
First Online: 29 October 2022
Declarations
:
: The research was considered against local ethics approval procedures, and it was determined that this was a policy evaluation and further approval was therefore not required. Participants provided YouGov® with pre-existing consent and as no personal identifying data was provided to the authors, further consent was not required.
: N/A.
: Dr. Simon ErridgeSimon Erridge is a junior doctor and undertakes paid consultancy work at Sapphire Medical Clinics. Simon Erridge is an honorary clinical research fellow at Imperial College London. The views expressed are those of the author(s) and not necessarily those of the NHS. Simon Erridge has no shareholdings in pharmaceutical companies.Dr. Ross CoomberRoss Coomber is a consultant orthopaedic surgeon, a director and a shareholder at Sapphire Medical Clinics and a consultant at St George’s Hospital, London. The views expressed are those of the author(s) and not necessarily those of the NHS. Ross Coomber has no shareholdings in pharmaceutical companies.Dr. Mikael H SodergrenMikael Sodergren is a director and a shareholder at Sapphire Medical Clinics and a consultant hepatopancreatobiliary surgeon at Imperial College NHS Trust, London. He is a senior clinical lecturer at Imperial College London. The views expressed are those of the author(s) and not necessarily those of the NHS. Mikael Sodergren is the chief medical officer at Curaleaf International.